SkinBioTherapeutics Plc
SBTX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £3 | £2 | £1 | £0 |
| % Growth | 94.1% | 43.1% | 934% | – |
| Cost of Goods Sold | £1 | £1 | £1 | £0 |
| Gross Profit | £2 | £1 | £1 | £0 |
| % Margin | 59.7% | 55.6% | 52.1% | 64% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | -£2 | £2 | £2 | £1 |
| SG&A Expenses | -£2 | £2 | £2 | £1 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £3 | -£0 | £0 | £0 |
| Operating Expenses | £2 | £2 | £2 | £1 |
| Operating Income | -£0 | -£1 | -£2 | -£1 |
| % Margin | -2.9% | -65.7% | -137.8% | -1,300.5% |
| Other Income/Exp. Net | £0 | -£0 | -£0 | -£0 |
| Pre-Tax Income | £0 | -£1 | -£2 | -£1 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | £0 | -£1 | -£2 | -£1 |
| % Margin | 11% | -65.6% | -139.8% | -1,252.6% |
| EPS | 0.001 | -0.005 | -0.008 | -0.008 |
| % Growth | 128.3% | 41.8% | -5.3% | – |
| EPS Diluted | 0.001 | -0.005 | -0.008 | -0.008 |
| Weighted Avg Shares Out | 259 | 223 | 195 | 177 |
| Weighted Avg Shares Out Dil | 259 | 223 | 195 | 177 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | £1 | -£1 | -£1 | -£1 |
| % Margin | 21.5% | -55.9% | -126.7% | -1,278% |